| Autor: |
Tyler H, Enos, Lawrence S, Feigenbaum, Heather W, Wickless |
| Rok vydání: |
2017 |
| Předmět: |
|
| Zdroj: |
International journal of dermatology. 56(12) |
| ISSN: |
1365-4632 |
| Popis: |
The utility of brentuximab vedotin (BV) in CD30A literature review was conducted, and we analyzed data from published trials and case reports obtained via search of Ovid-MEDLINEMean age at BV initiation was 60.8 years (67 - PC-ALCL; 60.1 - MF), and 4.1 therapies were attempted prior to BV (3.1 - PC-ALCL; 4.2 - MF). The overall response rate was 67.7% (100% - PC-ALCL; 63.9% - MF), with 16.2% of patients experiencing complete response (100% - PC-ALCL; 6.6% - MF). Mean time to clinical response was 5.3 and 9.3 weeks for PC-ALCL and MF, respectively. Mean response duration for patients with PC-ALCL was 7.6 and 7.8 months for MF. Peripheral neuropathy (57.2%) and fatigue (35.6%) were the most commonly reported adverse effects.This analysis summates the current evidence regarding the use of BV in treating CD30 |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text